Company File · BSE 526953 · Latest filing Q1 FY27
Standalone = this company only. Consolidated = including its subsidiaries.
Venus Remedies Ltd.
Data as of 19 Oct 2026 close · BSE · Latest results Q1 FY27
ISIN INE411B01019 · VENUSREM · Healthcare › Pharmaceuticals & Biotechnology
Price & valuation · BSE close, 19 Oct 2026
Above its usual level
- Sales growth
- +35.6%
- Profit growth
- +139.3%
- Op. margin
- 19.1%
- P/E
- 18.3×
- Usual P/E
- 16.7×
- Price/book
- 3.21×
- ROCE
- 21.9%
- ROE
- 16.8%
- Debt/equity
- 0.00×
- Promoter
- 41.76%
- Pledged
- 0.00%
Earnings callsNo earnings-call transcript from Venus Remedies in our data yet. When it files one on BSE, the call notes appear here within a few hours. See its call page
Is it expensive, and is it a good business?
Key ratios
In short Priced above its own usual level (P/E 18.3× vs 16.7×), earns high returns on capital (ROCE 21.9%) and has no debt.
What you pay Valuation
Buyers pay about ₹18 for every ₹1 the company earned per share over the last year. Above its 1-year median of 16.7×.
Latest BSE close ÷ last four quarters' basic EPS. Uses earnings per share from continuing operations, so a one-off gain from selling a business does not flatter it. As of 19th October 2026.
The share price is 3.2 times the accounting value of each share. Above its 1-year median of 2.1×.
Latest BSE close ÷ book value per share (equity ÷ shares) on the latest balance-sheet date. As of 19th October 2026.
The market values the company at 2.6 times its yearly sales.
Market value ÷ last 12 months' revenue. As of 19th October 2026.
The whole business (shares plus debt, minus cash) is valued at about 12.6 years of its operating profit.
Enterprise value ÷ last 12 months' EBITDA. As of 19th October 2026.
The P/E of 18.3 divided by EPS growth of 126.8% (counted as 100%) (the latest financial year vs the year before). Below 1 is often read as cheap for the growth; above 2 as expensive.
P/E ÷ 12-month EPS growth in % (the last four quarters vs the four before; when those are not all held, the latest financial year vs the year before). Growth above 100% counts as 100%; left blank when EPS fell or was below ₹1 a share a year earlier. Without one-off items when either year has large ones, as for the P/E. As of 19th October 2026.
The company paid ₹10.00 a share in the last 12 months (1 payout), 0.63% of today's share price.
Dividends per share with an ex-date in the last 12 months (restated for any split or bonus since) ÷ the latest BSE close. As of 19th October 2026.
How well it uses money Returns & strength
Each ₹100 of shareholders' money and debt earned about ₹21.9 before interest & tax.
Last 12 months' profit before interest & tax ÷ average (equity + borrowings). As of 31st March 2026.
For every ₹100 of shareholders' money, the company earned about ₹16.8 in a year.
Last 12 months' profit after tax (continuing operations where reported) ÷ average equity. As of 31st March 2026.
The money actually tied up in running the business (leaving out spare cash) earned about 18.4% after tax.
Last 12 months' operating profit after tax (profit before interest & tax × (1 − effective tax rate)) ÷ average invested capital (equity + borrowings − cash & bank balances). As of 31st March 2026.
Every ₹1 of assets generated about ₹0.97 of sales in a year.
Last 12 months' revenue ÷ average total assets. As of 31st March 2026.
Operating profit covered interest costs about 5054 times.
Last 12 months' profit before interest & tax ÷ finance costs. As of 30th June 2026.
The company reported no borrowings.
Borrowings ÷ shareholders' equity on the latest balance-sheet date. As of 31st March 2026.
Who owns it Ownership & more
The founders or parent group own 41.76% of the company.
Promoter & promoter group shareholding from the latest shareholding pattern filed with BSE. As of 30th September 2026.
Promoter holding did not change over the last quarter.
Latest quarter's promoter holding minus the previous quarter's. As of 30th September 2026.
Promoter holding, quarter by quarter
- Sep 202641.76%
- Jun 202641.76%
- Mar 202641.76%
- Dec 202541.76%
- Sep 202541.76%
Promoters reported no pledged shares.
Promoter group shares pledged ÷ all the promoter group's shares, from the shareholding pattern filed with BSE each quarter (other encumbrances, such as non-disposal undertakings, are not counted). As of 30th September 2026.
Pledged, quarter by quarter
- Sep 20260.00%
- Jun 20260.00%
- Mar 20260.00%
- Dec 20250.00%
- Sep 20250.00%
After paying for new plant & equipment, operations left ₹118 crore of cash.
Cash from operations − spending on plant & equipment, latest full year. As of 31st March 2026.
Free cash flow, year by year
- FY26₹118 Cr
- FY25₹77 Cr
Each share has a face (nominal) value of ₹10. It matters for dividends quoted as a percentage, not for valuation.
Face value per share as BSE lists it today.
About 1.34 crore shares were in issue.
BSE's count of listed shares (BSE's market cap ÷ its price), so splits, bonuses & new shares since the latest results are included. As of 19th October 2026.
Your ratios
Ratios you added. Your choices are remembered on this device.
The stock market values the company at about ₹2,128 crore.
Latest BSE close × BSE's count of listed shares. As of 19th October 2026.
Buying the whole business, including its debt and keeping its cash, would cost about ₹2,098 crore.
Market value + borrowings − cash & bank balances. As of 19th October 2026.
The company reported ₹116 crore of profit over the last four quarters.
Sum of the last four quarters' reported profit after tax. As of 30th June 2026.
Each share earned about ₹86.91 over the last year.
Sum of the last four quarters' basic EPS. Uses earnings per share from continuing operations, so a one-off gain from selling a business does not flatter it. As of 30th June 2026.
Each share is backed by about ₹497 of net assets on the books.
Shareholders' equity ÷ shares. As of 31st March 2026.
About ₹20.5 of every ₹100 of sales was left after running costs.
EBITDA ÷ revenue over the last four quarters. As of 30th June 2026.
About ₹12.8 of every ₹100 of sales became profit last quarter.
Profit after tax ÷ revenue for the latest quarter. As of 30th June 2026.
Sales were 35.6% higher than a year earlier.
Latest quarter's revenue vs the same quarter last year. As of 30th June 2026.
Profit was 139.3% higher than a year earlier.
Latest quarter's profit after tax vs the same quarter last year (continuing operations when a one-off discontinued item exists). As of 30th June 2026.
Short-term assets cover short-term bills 2.44 times.
Current assets ÷ current liabilities. As of 31st March 2026.
Customers take about 49 days to pay.
Trade receivables ÷ last 12 months' revenue × 365. As of 31st March 2026.
Stock on hand equals about 62 days of sales.
Inventories ÷ last 12 months' revenue × 365. As of 31st March 2026.
7.8% of pre-tax profit came from other income (interest, dividends, gains).
Other income ÷ profit before tax, last 12 months. As of 30th June 2026.
Each ₹1 of profit brought in ₹1.52 of operating cash.
Latest full year's cash from operations ÷ profit after tax. As of 31st March 2026.
Cash exceeds borrowings by ₹30 crore.
Cash & bank balances − borrowings. As of 31st March 2026.
The company paid about 23.4% of its pre-tax profit as tax.
Tax expense ÷ profit before tax (continuing operations), last 12 months. As of 30th June 2026.
Everything the company owns earned 13.1% in a year.
Last 12 months' profit ÷ average total assets. As of 31st March 2026.
Operating profit before interest, depreciation & tax was ₹166 crore.
Revenue − expenses + finance costs + depreciation, last four quarters. As of 30th June 2026.
Needs five financial years of cash flows.
Sum over five financial years of (cash from operations − capital expenditure).
The company spent ₹38 crore on plant & equipment.
Purchase of property, plant & equipment, latest full year. As of 31st March 2026.
No borrowings reported.
Current + non-current borrowings. As of 31st March 2026.
Foreign institutions own 3.14%.
Foreign institutional holding from the latest shareholding pattern. As of 30th September 2026.
Domestic institutions own 0.74%.
Domestic institutional holding (mutual funds, insurers, banks, pension funds). As of 30th September 2026.
The highest price in the last year was ₹2,043.15.
Highest intraday BSE price in the last 12 months (raw, not adjusted). As of 29th June 2026.
The lowest price in the last year was ₹432.
Lowest intraday BSE price in the last 12 months (raw, not adjusted). As of 28th October 2025.
The share price moved 251.4% over the last year.
Close today ÷ close a year ago − 1 (raw prices, dividends not included). As of 19th October 2026.
About 12% of the last year's earnings per share was paid out as dividends.
Dividends per share with an ex-date in the last 12 months ÷ the last four quarters' EPS. As of 30th June 2026.
Needs four financial years of results (three years of growth).
Compound annual growth in revenue over three financial years.
Needs four financial years of results (three years of growth).
Compound annual growth in profit after tax over three financial years.
Tap the i beside any ratio for a plain explanation.
How these are worked out
Price-based ratios use the latest BSE close (19th October 2026). Share count 1.34 crore, from paid-up capital in the 19th October 2026 filing. Figures are consolidated.
What you pay: Higher numbers mean you pay more for each rupee the company earns or owns.
How well it uses money: Higher returns mean each rupee in the business earns more. Lower debt means less strain.
Who owns it: A steady promoter stake with nothing pledged is a calm sign.
+ Add your own ratios
Your choices are remembered on this device.
Last 4 quarters ₹ crore · Consolidated
| ₹ crore | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Revenue from operations | 192.8 | 180.3 | 259.4 | 178.9 |
| EBITDA | 31.0 | 37.5 | 63.4 | 34.2 |
| Operating margin | 16.1% | 20.8% | 24.4% | 19.1% |
| Profit after tax | 20.1 | 25.6 | 47.5 | 23.0 |
| Basic EPS (₹) | 15.06 | 19.14 | 35.53 | 17.18 |
Latest filings BSE
Corporate announcements 5
- 16 Oct 2026Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets
- 14 Oct 2026Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests
- 14 Oct 2026Board Meeting Intimation for Notice Of Board Meeting Dated 26Th October 2026.
Quarterly results 0
None in the filings we hold.
Conference calls 0
None in the filings we hold.
Investor presentations 0
None in the filings we hold.
Members see every filing, and what each means for the company in Corporate Intelligence.
The full Company File
- Price, P/E, P/B & returns charts
- Growth vs last year, explained
- Cash from operations vs profit
- Accounts checks
- Who owns it
- 8 quarters, balance sheet & cash flow
- Every BSE filing, in four panels
- Excel & CSV downloads
Education & analysis only, not investment advice or a recommendation.